Trial Profile

An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients ≥ 65 Years With Acute Myeloid Leukemia

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jan 2021 Protocol was amended to add other Schedules (B, C, and D) with reduced volasertib dose density with the aim to improve treatment tolerability.
01 Jan 2021 Results published in the International Journal of Hematology
14 Dec 2016 Status changed from active, no longer recruiting to discontinued.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com